Cargando…

Tendering and biosimilars: what role for value-added services?

Background: Access to biologic medicines (including biosimilars) across Europe is largely governed by a process of tendering conducted by health authorities. Over-reliance on treatment costs in awarding tenders has the potential to hinder competition and undermine the long-term sustainability of bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Simoens, Steven, Cheung, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968494/
https://www.ncbi.nlm.nih.gov/pubmed/32002174
http://dx.doi.org/10.1080/20016689.2019.1705120
_version_ 1783489144481120256
author Simoens, Steven
Cheung, Raymond
author_facet Simoens, Steven
Cheung, Raymond
author_sort Simoens, Steven
collection PubMed
description Background: Access to biologic medicines (including biosimilars) across Europe is largely governed by a process of tendering conducted by health authorities. Over-reliance on treatment costs in awarding tenders has the potential to hinder competition and undermine the long-term sustainability of biosimilars. Objective: To assess the extent and impact of consideration of ‘value-added services’ (VAS) in tendering for biosimilars, we conducted a narrative review of published literature. Results: Findings from survey-based publications indicated that tendering practices for biosimilars are widely used, with cost being the main determinant of success and little detail being available on other criteria where these apply. Criteria (of therapeutic and technical interest) beyond price were included in one tendering specification for infliximab (originator and biosimilars), while a separate tender for the same product included VAS in the form of therapeutic drug monitoring, measurement of antibodies and calprotectin. Conclusions: Published evidence concerning inclusion of VAS in tendering for biosimilars is lacking. Development and implementation of standardized criteria and methods of assessment for tenders may avoid manufacturers facing segmented markets, encourage competition and the longer-term sustainability of biosimilars, and realize the healthcare system and patient benefits these treatments can bring.
format Online
Article
Text
id pubmed-6968494
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Routledge
record_format MEDLINE/PubMed
spelling pubmed-69684942020-01-30 Tendering and biosimilars: what role for value-added services? Simoens, Steven Cheung, Raymond J Mark Access Health Policy Review Article Background: Access to biologic medicines (including biosimilars) across Europe is largely governed by a process of tendering conducted by health authorities. Over-reliance on treatment costs in awarding tenders has the potential to hinder competition and undermine the long-term sustainability of biosimilars. Objective: To assess the extent and impact of consideration of ‘value-added services’ (VAS) in tendering for biosimilars, we conducted a narrative review of published literature. Results: Findings from survey-based publications indicated that tendering practices for biosimilars are widely used, with cost being the main determinant of success and little detail being available on other criteria where these apply. Criteria (of therapeutic and technical interest) beyond price were included in one tendering specification for infliximab (originator and biosimilars), while a separate tender for the same product included VAS in the form of therapeutic drug monitoring, measurement of antibodies and calprotectin. Conclusions: Published evidence concerning inclusion of VAS in tendering for biosimilars is lacking. Development and implementation of standardized criteria and methods of assessment for tenders may avoid manufacturers facing segmented markets, encourage competition and the longer-term sustainability of biosimilars, and realize the healthcare system and patient benefits these treatments can bring. Routledge 2019-12-22 /pmc/articles/PMC6968494/ /pubmed/32002174 http://dx.doi.org/10.1080/20016689.2019.1705120 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Simoens, Steven
Cheung, Raymond
Tendering and biosimilars: what role for value-added services?
title Tendering and biosimilars: what role for value-added services?
title_full Tendering and biosimilars: what role for value-added services?
title_fullStr Tendering and biosimilars: what role for value-added services?
title_full_unstemmed Tendering and biosimilars: what role for value-added services?
title_short Tendering and biosimilars: what role for value-added services?
title_sort tendering and biosimilars: what role for value-added services?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968494/
https://www.ncbi.nlm.nih.gov/pubmed/32002174
http://dx.doi.org/10.1080/20016689.2019.1705120
work_keys_str_mv AT simoenssteven tenderingandbiosimilarswhatroleforvalueaddedservices
AT cheungraymond tenderingandbiosimilarswhatroleforvalueaddedservices